Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme.

Trial Profile

Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2018

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Oct 2018 Status changed from active, no longer recruiting to completed.
    • 31 Aug 2018 Biomarkers information updated
    • 06 Dec 2013 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top